Neovacs SA AI Stock Analysis
Want to see FR:ALNEV full AI Analyst Report?
Neovacs SA (ALNEV) AI Stock Analysis
Neovacs SA
(Paris:ALNEV)
Weak financial performance from persistent losses and cash burn is the dominant factor, further pressured by bearish technical indicators in this high-risk early-stage biotech.
Neovacs SA (ALNEV) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 124.97K
- Dividend Yield
- ―
- Average Volume (3M)
- 110.47K
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 1.78
- Revenue Growth
- -9.52%
- EPS Growth
- 100.00%
- Country
- France
- Employees
- 16
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Neovacs SA Business Overview & Revenue Model
Company Description
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its p...
How the Company Makes Money
Neovacs’ business model is primarily biotechnology R&D-driven. The company would be expected to generate revenue through (1) out-licensing or co-development agreements for its Kinoid platform and/or individual drug candidates, typically structured wi...
Neovacs SA Financial Statement Overview
Summary
Highly volatile low revenue, persistent heavy losses, and ongoing cash burn typical of early-stage biotech, partially offset by low debt providing balance sheet stability.
Income Statement
15Very NegativeBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 228.77K | 161.78K | 533.41K | 366.35K | 1,112 | 22.59K |
| Gross Profit | -3.20M | -4.52M | -6.75M | 42.42K | -6.26M | -7.60M |
| EBITDA | -5.24M | -5.24M | -8.45M | -6.61M | -3.61M | -10.38M |
| Net Income | -4.90M | -4.90M | -8.74M | -32.91M | -3.55M | -11.84M |
Balance Sheet | ||||||
| Total Assets | 22.14M | 22.14M | 47.53M | 22.07M | 49.28M | 48.55M |
| Cash, Cash Equivalents and Short-Term Investments | 571.79K | 571.79K | 887.09K | 435.45K | 6.76M | 33.09M |
| Total Debt | 537.20K | 537.20K | 650.59K | 230.37K | 1.20M | 1.03M |
| Total Liabilities | 4.10M | 4.10M | 3.71M | 4.01M | 5.05M | 4.65M |
| Stockholders Equity | 18.03M | 18.03M | 43.82M | 18.06M | 44.23M | 43.90M |
Cash Flow | ||||||
| Free Cash Flow | -5.04M | -5.04M | -2.12M | -3.68M | -4.60M | -10.26M |
| Operating Cash Flow | -5.03M | -5.03M | -1.91M | -3.60M | -4.45M | -9.91M |
| Investing Cash Flow | -446.17K | -446.17K | -11.08M | 1.45M | -31.56M | -18.81M |
| Financing Cash Flow | 5.62M | 5.62M | 6.79M | 1.70M | 9.99M | 51.75M |
Neovacs SA Peers Comparison
Overall Rating
FR:VLA51Neutral
FR:OSE49Neutral
FR:TNG48Neutral
FR:ABVX44Neutral
FR:ALNEV41Neutral
FR:DBV40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | EUR 488.58M | -2.85 | -152.15% | ― | -27.19% | -117.39% | |
| 49Neutral | EUR 40.77M | -1.02 | -96.73% | ― | -96.25% | -197.89% | |
| 48Neutral | EUR 200.64M | -4.31 | -29.36% | ― | 189.81% | 38.50% | |
| 44Neutral | EUR 6.93B | -16.79 | -85.88% | ― | ― | ― | |
| 41Neutral | EUR 124.97K | 0.00 | -26.52% | ― | -9.52% | 100.00% | |
| 40Underperform | EUR 618.29M | -3.61 | -121.83% | ― | ― | 45.11% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALNEV | Neovacs SA | 0.07 | -263.93 | -99.97% | |
| FR:ABVX | Abivax SA | 76.90 | -21.80 | -22.09% | |
| FR:DBV | Dbv Technologies SA (UK) | 1.87 | -0.53 | -22.00% | |
| FR:TNG | Transgene SA | 0.71 | -0.58 | -44.57% | |
| FR:VLA | Valneva (0OB3) | 2.60 | -1.18 | -31.13% | |
| FR:OSE | OSE Immunotherapeutics | 1.68 | -3.74 | -68.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
